Sacaan A I, Menzaghi F, Dunlop J L, Correa L D, Whelan K T, Lloyd G K
SIBIA, La Jolla, California, USA.
J Pharmacol Exp Ther. 1996 Feb;276(2):509-15.
The effect of the neuronal acetylcholine-gated ion channel receptor agonist (+/-)-epibatidine was studied on neurotransmitter release in vitro and motor behavior in vivo. (+/-)-Epibatidine (3-300 nM) caused a concentration- and calcium-dependent release of [3H]-dopamine from striatal slices and [3H]-norepinephrine release from hippocampal and thalamic slices. (+/-)-Epibatidine-induced neurotransmitter release was inhibited in all three regions by mecamylamine (3 microM). In contrast, D-tubocurarine (10-100 microM) inhibited only (+/-)-epibatidine-induced [3H]-norepinephrine release from the hippocampus and the thalamus. Conversely, dihydro beta-erythroidine (3-100 microM) inhibited (+/-)-epibatidine-induced [3H]-dopamine release in the striatum without significantly altering [3H]-norepinephrine release from either the hippocampus or the thalamus. This is consistent with the observation that different nAChRs modulate dopamine release as compared with norepinephrine release. The effect of (+/-)-epibatidine on both [3H]-dopamine and [3H]-norepinephrine release was tetrodotoxin-sensitive, suggesting the involvement of sodium channels. (+/-)-Epibatidine (1-3 micrograms/kg s.c.) produced ipsilateral turning in the unilaterally [6(OH)-DA]-lesioned rat. This effect was mimicked by (-)-nicotine (0.35 mg/kg s.c.). Both (+/-)-epibatidine- and (-)-nicotine-induced turning were significantly inhibited by mecamylamine (3 mg/kg s.c.), indicating that the turning response was mediated by nAChRs. (+/-)-Epibatidine also increased locomotor activity in a dose-dependent manner. (+/-)-Epibatidine-induced hyperactivity was blocked by D1 and D2 receptor antagonists, SCH 23390 and eticlopride, respectively, suggesting that both dopamine receptor subtypes might be required for the locomotor effect of (+/-)-epibatidine. These results demonstrate that (+/-)-epibatidine displays nAChR agonist activity in the rat CNS and that certain effects are mediated via nAChR-stimulated catecholamine release and subsequent activation of corresponding receptors.
研究了神经元乙酰胆碱门控离子通道受体激动剂(±)-埃博霉素对体外神经递质释放和体内运动行为的影响。(±)-埃博霉素(3-300 nM)可引起纹状体切片中[3H]-多巴胺以及海马体和丘脑切片中[3H]-去甲肾上腺素浓度和钙依赖性释放。美加明(3 microM)在所有三个区域均抑制(±)-埃博霉素诱导的神经递质释放。相比之下,筒箭毒碱(10-100 microM)仅抑制(±)-埃博霉素诱导的海马体和丘脑中[3H]-去甲肾上腺素的释放。相反,二氢β-刺桐啶(3-100 microM)抑制(±)-埃博霉素诱导的纹状体中[3H]-多巴胺释放,而不会显著改变海马体或丘脑中[3H]-去甲肾上腺素的释放。这与不同的烟碱型乙酰胆碱受体调节多巴胺释放与去甲肾上腺素释放的观察结果一致。(±)-埃博霉素对[3H]-多巴胺和[3H]-去甲肾上腺素释放的影响对河豚毒素敏感,表明钠通道参与其中。(±)-埃博霉素(1-3微克/千克皮下注射)在单侧[6(OH)-DA]损伤的大鼠中产生同侧旋转。(-)-尼古丁(0.35毫克/千克皮下注射)可模拟此效应。美加明(3毫克/千克皮下注射)显著抑制(±)-埃博霉素和(-)-尼古丁诱导的旋转,表明旋转反应是由烟碱型乙酰胆碱受体介导的。(±)-埃博霉素还以剂量依赖性方式增加运动活性。(±)-埃博霉素诱导的多动分别被D1和D2受体拮抗剂SCH 23390和依托必利阻断,表明两种多巴胺受体亚型可能是(±)-埃博霉素运动效应所必需的。这些结果表明,(±)-埃博霉素在大鼠中枢神经系统中表现出烟碱型乙酰胆碱受体激动剂活性,并且某些效应是通过烟碱型乙酰胆碱受体刺激的儿茶酚胺释放以及随后相应受体的激活介导的。